Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the top cheap stocks under $20, with recent regulatory milestones enhancing its investment appeal [1] Regulatory Milestones - The FDA approved Viatris' octreotide acetate for injectable suspension, a generic version of Sandostatin® LAR Depot, for treating acromegaly and certain types of diarrhea associated with tumors [1] - The FDA accepted the New Drug Application (NDA) for Viatris' investigational low dose estrogen weekly patch for contraception [2] - The FDA cleared the Investigational New Drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with plans for a Phase 1/2 clinical trial starting in H1 2026 [2] - The Japan Pharmaceuticals and Medical Devices Agency (PMDA) accepted the Japanese New Drug Application (J-NDA) for pitolisant in obstructive sleep apnea syndrome, with plans to submit a J-NDA for narcolepsy by year-end [3] Company Overview - Viatris is a global healthcare company providing a wide range of pharmaceutical products across various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare [4] - The company's operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets [4]